Initial Pharmacoeconomic Data Demonstrates Cost Benefits Of Altrazeal

04/07/2014

Addison, Texas, April 7, 2014; ULURU Inc. (OTCQB: ULUR), is pleased to provide an update on the pharmacoeconomic analysis being conducted in Europe on Altrazeal®, the Company’s innovative wound dressing. The purpose of this pharmacoeconomic analysis is to evaluate both the cost and healing benefits of Altrazeal® when compared to conventional dressings and advanced moist wound healing products.
Read More